Core Viewpoint - Medike (688079.SH) plans to raise up to 700 million yuan through a private placement of shares, with the net proceeds intended for investment in MEMS optical system manufacturing, semiconductor bonding prism industrialization projects, and to supplement working capital [1] Group 1 - The total amount to be raised is not to exceed 700 million yuan [1] - The funds will be allocated to specific projects including MEMS optical system manufacturing and semiconductor bonding prism industrialization [1] - The company aims to enhance its working capital through this fundraising initiative [1]

证券代码：688079 证券简称：美迪凯 公告编号：2025-046 杭州美迪凯光电科技股份有限公司 2024 年股票期权与限制性股票激励计划首次授予第一类 限制性股票第一个解除限售期解除限售暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 3,506,280股。 本次股票上市流通总数为3,506,280股。 本次股票上市流通日期为2025 年 11 月 21 日。 杭州美迪凯光电科技股份有限公司（以下简称 "公司"或 "美迪凯"）于 2025 年 10 月 30 日召开的第三届董事会薪酬与考核委员会第二次会议和第三届董事会第 六次会议，审议通过了《关于公司 2024 年股票期权与限制性股票激励计划首次授予 第一类限制性股票第一个解除限售期解除限售条件成就的议案》，根据公司 2024 年 股票期权与限制性股票激励计划（以下简称"本次激励计划"）等的相关规定及公 司 2024 年第一次临时股东大会的授权，董事会认为本次激励计划首次授予第 ...

证券代码：688079 证券简称：美迪凯 公告编号：2025-045 杭州美迪凯光电科技股份有限公司 关于2024年股票期权与限制性股票激励计划首次授予股 票期权第一个行权期自主行权实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 行权安排：本激励计划首次授予部分第一个行权期为自首次授权日起12个 月后的首个交易日起至首次授权日起24个月内的最后一个交易日当日止。本次行 权有效日期为2025年11月18日至2026年11月17日（行权日须为交易日），行权所 得股票可于行权日（T日）后的第二个交易日（T+2日）上市交易。根据行权手续 办理情况，实际可行权期限为2025年11月21日至2026年11月17日（行权日须为交 易日）。 杭州美迪凯光电科技股份有限公司（以下简称"公司"）于2025年10月30日 召开第三届董事会第六次会议，审议通过了《关于2024年股票期权与限制性股票 激励计划首次授予股票期权第一个行权期行权条件成就的议案》，认为公司 《2024年股票期权激励计划（草案）》（以下简称"《激励 ...

证券代码：688079 证券简称：美迪凯 公告编号：2025-044 杭州美迪凯光电科技股份有限公司 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 05 日（星期三）至 11 月 11 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ipo@chinamdk.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 杭州美迪凯光电科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 12 日（星期三）09:00-10:00 举行 2025 年第三季 度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2025 年 11 月 12 日（星期三）09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 ...

Core Viewpoint - The company has announced a total impairment provision of 13,378,501.84 yuan for the first three quarters of 2025, reflecting a cautious approach to accurately represent its financial status and asset values [1][3]. Summary by Sections Overview of Impairment Provision - The total impairment provision for the first three quarters of 2025 amounts to 13,378,501.84 yuan [1]. Credit Impairment Loss - The company recognized a credit impairment loss of 1,184,918.50 yuan based on expected credit losses for accounts receivable, other receivables, and notes receivable [2]. Asset Impairment Loss - The company calculated an asset impairment loss of 12,193,583.34 yuan, determined by comparing the cost of inventory to its net realizable value [2]. Impact on Financials - The total impact of the credit and asset impairment losses on the company's consolidated profit for the first three quarters of 2025 is a reduction of 13,378,501.84 yuan, not accounting for income tax effects [3]. Compliance and Operational Impact - The impairment provision complies with relevant accounting standards and accurately reflects the company's financial condition as of September 30, 2025, without affecting normal operations [4].

Group 1 - The company Meidike (SH 688079) announced on October 31 that it has recognized a total of approximately 13.38 million yuan in credit impairment losses and asset impairment losses for the first three quarters of 2025, which will impact the consolidated profit total by approximately -13.38 million yuan [1] - The impairment amount was based on preliminary calculations by the company's finance department and has not been audited by an accounting firm, indicating a need for investors to be cautious about investment risks [1] - As of the time of reporting, Meidike's market capitalization stands at 5 billion yuan [2]

一、本次计提资产减值准备的情况概述 公司2025年前三季度对各项资产计提减值准备合计为13,378,501.84元，具体情 况如下表： 单位：元 币种：人民币 | 项目 | 本期金额 | | --- | --- | | 信用减值损失（损失以"－"号填列） | -1,184,918.50 | | 资产减值损失（损失以"－"号填列） | -12,193,583.34 | | 合计 | -13,378,501.84 | 证券代码：688079 证券简称：美迪凯 公告编号：2025-043 杭州美迪凯光电科技股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州美迪凯光电科技股份有限公司（以下简称"公司"）根据《企业会计准则》 和公司会计政策等相关规定，为真实、准确、公允地反映公司财务状况、资产价 值及经营成果，基于谨慎性原则，公司对截至2025年9月30日合并报表中主要资产 进行了减值测试，对合并报表范围内可能存在减值迹象的相关资产计提了相应的减 值准备。现将相关情况公告 ...

Group 1 - The core viewpoint of the news is that Meidike (688079.SH) reported a decrease in institutional holdings in its third-quarter report for 2025, with a total of 10 institutional investors holding 256 million shares, accounting for 62.77% of the total share capital, which is a decline of 3.61 percentage points from the previous quarter [1] - The top ten institutional investors include entities such as Hangzhou Meidike Self-owned Capital Investment Partnership and Meidike Holdings Group, with their combined holding ratio remaining significant despite the decline [1] - In terms of public funds, one new public fund was disclosed this quarter, while 71 public funds were not disclosed compared to the previous quarter, indicating a potential shift in investment strategies among public funds [1] Group 2 - From the perspective of foreign investment, there was a decrease in holdings from one foreign fund, Hong Kong Fengsheng Jiamei (International) Investment Co., Ltd., with a reduction of 2.99% [2]

Core Viewpoint - Meidike, a leading company in the optical semiconductor field, is facing challenges in revenue and profitability, with significant room for improvement compared to industry peers [2][3][5]. Group 1: Company Overview - Meidike was established on August 25, 2010, and went public on March 2, 2021, on the Shanghai Stock Exchange, with its registered office in Hangzhou, Zhejiang Province [1]. - The company specializes in optical optoelectronics, semiconductor optics, micro-nano circuits, semiconductor packaging, and smart terminal research, manufacturing, and sales [1]. Group 2: Financial Performance - In Q3 2025, Meidike achieved a revenue of 451 million yuan, ranking 19th among 26 companies in the industry, significantly lower than the top competitor, O-film, with 15.816 billion yuan [2]. - The net profit for the same period was -83.2248 million yuan, placing it at the bottom of the industry rankings, with the industry leader, Crystal Optoelectronics, reporting a net profit of 988 million yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Meidike's debt-to-asset ratio was 58.88%, higher than the previous year's 49.81% and above the industry average of 36.11% [3]. - The gross profit margin for the same period was 18.88%, down from 20.86% year-on-year and below the industry average of 26.98% [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.01% to 10,800, while the average number of circulating A-shares held per shareholder increased by 0.01% to 37,000 [5]. Group 5: Future Outlook - Longcheng Securities noted that Meidike is a leading player in the optical semiconductor sector, with its product matrix entering a harvest phase, including advancements in semiconductor processes and new product certifications [5]. - The company is expected to report net profits of -81 million yuan, 150 million yuan, and 266 million yuan for the years 2025, 2026, and 2027, respectively [5].

Core Viewpoint - Meidike has disclosed progress on its 2024 stock option and restricted stock incentive plan, confirming the achievement of performance conditions for the first exercise period and the first release period for restricted stocks [1][3][4]. Group 1: Stock Options and Restricted Stocks - The company will repurchase and cancel 32,000 shares of restricted stocks and stock options due to the departure of two incentive plan participants [2]. - The repurchase price for the canceled stocks will be 3.69 yuan per share, funded by the company's own resources [2]. - A total of 3.5063 million shares of restricted stocks will be released from restrictions, involving 339 incentive participants, with a company-level performance assessment showing a revenue growth rate of 51.38% [4]. Group 2: Performance Conditions - The first exercise period for the stock options has met all conditions, with a required revenue growth rate of at least 40% for 2024, while the actual growth was 51.38%, reaching 486 million yuan [3]. - All 339 incentive participants achieved an "A" rating in their personal performance assessments, allowing them to fully exercise their options [3]. Group 3: Legal Compliance and Future Steps - The legal opinion confirms that the repurchase, exercise conditions, and release conditions have received necessary approvals and comply with relevant regulations [5]. - The company is required to fulfill information disclosure obligations and complete the necessary registration procedures for stock repurchase, option exercise, and release of restricted stocks [5].